GUANGZHOU, China - TelAve -- POMDOCTOR LIMITED (N A S D A Q: POM) $POM is entering the final stretch of September with a rapidly developing story centered on one of healthcare technology's most closely watched opportunities: combining artificial intelligence, real-world healthcare data, connected devices, physician resources and payment infrastructure into a more continuous model of patient care.

The company's latest update adds another important layer to that strategy, highlighting continued optimization of its proprietary AI chronic disease management system, expanding applications for real-world data (RWD), and integrated in-hospital and out-of-hospital chronic disease management pilots.

For investors watching the evolving digital-health landscape, POM's recent announcements show a company attempting to move beyond the traditional online healthcare model and toward a more integrated predictive healthcare infrastructure.

The Latest Development: AI + Real-World Data

POMDOCTOR says it has completed multiple rounds of optimization of its AI chronic disease management system using multidimensional real-world healthcare data.

That data can include:

• Medication and diagnosis/treatment information
• Patient behavioral and monitoring data
• Healthcare payment information
• Physiological and remote patient monitoring data

The company's roadmap is designed around capabilities such as risk identification, personalized chronic disease intervention and physician-patient follow-up workflows. Importantly, POM describes the system as a continuing feedback loop: healthcare data generated through patient management can be processed back into the system to refine AI models and support physicians in developing increasingly personalized management strategies.

That creates a potentially significant distinction in POM's strategy. Rather than treating digital healthcare as a single online transaction, the company is working toward an ongoing data-driven relationship between patient, physician and technology.

A Four-Tier Revenue Opportunity Is Taking Shape

POM has also been emphasizing commercialization of its real-world data capabilities.

The company says its RWD initiatives include pharmaceutical real-world studies, evidence-based research cooperation, B2B healthcare data services and chronic disease management collaborations with third-party healthcare institutions.

That matters because RWD can potentially create value across multiple areas of the healthcare ecosystem. Pharmaceutical companies, healthcare providers, researchers and digital-health organizations can all have applications for properly structured healthcare information.

More on TelAve News

• LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
• Security Planning Tips For Your Holiday Event From Access Patrol Services
• Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
• Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
• Kitchen Table Economics: An Invitation to Think Differently

POM has identified pharmaceutical RWS/RWD services as a core value driver within its diversified revenue structure. The opportunity is therefore not limited to patient-facing healthcare services; it potentially extends into data-related commercial applications as well.

"Hardware + AI + Payment" Becomes a Major Theme

One of POMDOCTOR's most recent announcements, dated September 24, takes the strategy another step forward.

The company highlighted what it calls a differentiated "hardware + AI + payment" healthcare infrastructure model, with the goal of integrating continuous health monitoring, AI-powered analysis, physician intervention, healthcare payment and fulfillment into a unified ecosystem.

The significance of this strategy is that POM is attempting to connect multiple pieces of the healthcare journey rather than concentrating on a single service.

Wearable technologies can provide health information. AI can process and analyze that information. Physicians can provide intervention and follow-up. Payment infrastructure can facilitate the financial side of healthcare services.

The company believes that connecting those components could support a more continuous and predictive healthcare model.

U.S. Expansion Adds Another Potential Catalyst

POM's strategy is also becoming increasingly international.

On August 27, the company announced that it had formally begun preparations for entry into the U.S. healthcare market. POM said it had begun recruiting U.S.-based leadership and operational personnel, assessing the U.S. market, developing a local compliance and regulatory framework, advancing product localization and engaging in exploratory discussions with potential U.S. healthcare partners.

The initial strategy is expected to emphasize pilot validation, including potential applications in remote patient monitoring and chronic disease management.

For investors, the U.S. initiative creates another development path to watch as POM works to determine how its technology and healthcare infrastructure could translate into another major healthcare market.

Investor Visibility Is Increasing

POMDOCTOR also participated in the 28th Annual H.C. Wainwright Global Investment Conference in September, with a company presentation made available to investors. The event provided another opportunity for the company to present its strategy and evolving business model to the investment community.

The timing is notable. POM is simultaneously discussing AI optimization, RWD commercialization, U.S. expansion and its broader infrastructure strategy.

That gives investors several distinct areas to monitor as the company moves forward.

Nasdaq Compliance Adds Another Important Piece

More on TelAve News

• Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
• CB Stuffer Announces Private Sale to Secure Future of Brand Growth
• The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
• Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
• Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition

Earlier this summer, POMDOCTOR announced that it had regained compliance with Nasdaq's minimum $1.00 bid-price requirement. Nasdaq determined that POM's ADS closing bid price had remained at or above $1.00 for the required 10 consecutive business days from June 25 through July 9, 2026.

The company's ability to regain compliance removed that particular Nasdaq listing issue and allowed management to focus attention on its operating and strategic initiatives.

What Investors Will Be Watching Next

The story around N A S D A Q: POM is increasingly centered on execution.

The key developments to watch include:

• Further optimization and deployment of POM's AI chronic disease management system
• Commercialization of real-world healthcare data and pharmaceutical RWS/RWD services
• Progress from integrated in-hospital and out-of-hospital chronic disease management pilots
• Development of the company's U.S. market strategy and potential partnerships
• Expansion of the "hardware + AI + payment" infrastructure model
• Evidence of how these initiatives translate into revenue and scalable commercial operations

POMDOCTOR's latest update describes a company attempting to evolve from episodic healthcare services toward continuous, data-driven and predictive chronic disease management. Its stated architecture combines multi-source data standardization, risk identification, physician-assisted intervention and continuous AI model iteration.

The Bigger Picture for $POM

POMDOCTOR is positioning itself at the intersection of several major healthcare technology trends: artificial intelligence, remote monitoring, wearable technology, real-world data and digital healthcare services.

The company is still in an execution phase, and its forward-looking plans carry the usual risks and uncertainties associated with emerging healthcare technology businesses. POM itself cautions investors that actual results may differ materially from forward-looking expectations.

Nevertheless, the pace and breadth of the company's recent announcements make POMDOCTOR LIMITED (NAS DAQ: POM) a company with several developing catalysts to watch closely.

With AI development accelerating, RWD commercialization expanding, U.S. market preparations underway and the "hardware + AI + payment" model becoming a central part of its strategy, POM is working to build something considerably broader than a conventional online healthcare platform.

For investors following the next generation of digital healthcare infrastructure, the coming months could provide important evidence of how effectively POMDOCTOR can turn its technology, data and physician network into scalable commercial opportunities.

For more information on POM visit:  https://ir.7shiliu.com/

Media Contact
Company Name: POMDOCTOR Limited (N A S D A Q: POM)
Contact Person: Zhenyang Shi, Chairman and Chief Executive Officer
Email:  ir@7lk.com
Phone: 86 020-6231 2277
Country: China

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website